These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2556232)

  • 1. A comparison of two APTT reagents which use silica activators.
    Ray MJ; Hawson GA
    Clin Lab Haematol; 1989; 11(3):221-32. PubMed ID: 2556232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance characteristics of a new synthetic APTT reagent.
    Ts'ao C; Neofotistos D; Oropeza M; Rogan M; Santos M
    Clin Lab Haematol; 1998 Oct; 20(5):307-13. PubMed ID: 9807679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors.
    Favaloro EJ; Kershaw G; Mohammed S; Lippi G
    Semin Thromb Hemost; 2019 Feb; 45(1):22-35. PubMed ID: 30630206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer.
    Shetty S; Ghosh K; Mohanty D
    Blood Coagul Fibrinolysis; 2003 Jul; 14(5):493-7. PubMed ID: 12851537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the activated partial thromboplastin time for the diagnosis of congenital coagulation disorders: problems and possible solutions.
    Barna L; Triplett DA
    Ric Clin Lab; 1989; 19(4):345-54. PubMed ID: 2517350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated partial thromboplastin time reagents: an evaluation.
    Howarth S
    Br J Biomed Sci; 1993 Jun; 50(2):109-13. PubMed ID: 8219915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trials of commercial reagents in anion-exchange coagulation procedures: ortho diagnostics.
    Branson HE; Schottinger JE; Fagin AR; Puri SL; Roohk V
    Am J Clin Pathol; 1984 Oct; 82(4):432-5. PubMed ID: 6475839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of three activated partial thromboplastin time reagents to coagulation factor deficiencies.
    Turi DC; Peerschke EI
    Am J Clin Pathol; 1986 Jan; 85(1):43-9. PubMed ID: 3940420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APTT reagent with ellagic acid as activator shows adequate lupus anticoagulant sensitivity in comparison to silica-based reagent.
    Kumano O; Ieko M; Naito S; Yoshida M; Takahashi N
    J Thromb Haemost; 2012 Nov; 10(11):2338-43. PubMed ID: 22909048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consequences for the APTT due to direct action of factor XIa on factor X, resulting in bypassing factors VIII-IX.
    Kluft C; van Leuven CJ
    Thromb Res; 2015 Jan; 135(1):198-204. PubMed ID: 25467084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the sensitivity of commercial APTT reagents in the detection of mild coagulopathies.
    Marlar RA; Bauer PJ; Endres-Brooks JL; Montgomery RR; Miller CM; Schanen MM
    Am J Clin Pathol; 1984 Oct; 82(4):436-9. PubMed ID: 6475840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability in heparin sensitivity of APTT reagents.
    Bjornsson TD; Nash PV
    Am J Clin Pathol; 1986 Aug; 86(2):199-204. PubMed ID: 3739971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An attempt to standardize APTT reagents used to monitor heparin therapy.
    Ray M; Carroll P; Smith I; Hawson G
    Blood Coagul Fibrinolysis; 1992 Dec; 3(6):743-8. PubMed ID: 1336984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of factor VIII:C and factor IX sensitivity of different commercial APTT reagents for canine plasma].
    Mischke R
    Berl Munch Tierarztl Wochenschr; 1999; 112(10-11):394-9. PubMed ID: 10598358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants.
    Denis-Magdelaine A; Flahault A; Verdy E
    Haemostasis; 1995; 25(3):98-105. PubMed ID: 7607585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of bedside prothrombin time and activated partial thromboplastin time measurement by coagulation analyzer CoaguCheck Plus in various clinical settings.
    Ruzicka K; Kapiotis S; Quehenberger P; Handler S; Hornykewycz S; Michitsch A; Huber K; Clemens D; Susan M; Pabinger I; Eichinger S; Jilma B; Speiser W
    Thromb Res; 1997 Sep; 87(5):431-40. PubMed ID: 9306617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants.
    Alving BM; Baldwin PE; Richards RL; Jackson BJ
    Thromb Haemost; 1985 Oct; 54(3):709-12. PubMed ID: 3937268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies.
    Toulon P; Eloit Y; Smahi M; Sigaud C; Jambou D; Fischer F; Appert-Flory A
    Int J Lab Hematol; 2016 Aug; 38(4):389-96. PubMed ID: 27185477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromogenic substrates for activated partial thromboplastin time testing: are they worth using?
    Tripodi A
    Ric Clin Lab; 1989; 19(4):355-8. PubMed ID: 2517351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.